Regenerative Medical Technology Group Inc. Files Q2 2025 10-Q

TL;DR

Regenerative Medical Tech files Q2 10-Q. Financials updated.

AI Summary

Regenerative Medical Technology Group Inc. filed its 10-Q for the quarterly period ended June 30, 2025. The company, formerly known as MESO NUMISMATICS, INC., is incorporated in Nevada and headquartered in Boca Raton, Florida. The filing details its financial performance and operations for the specified period.

Why It Matters

This filing provides investors and stakeholders with an update on the company's financial health and operational status for the second quarter of 2025.

Risk Assessment

Risk Level: low — This is a standard quarterly filing and does not inherently present new risks.

Key Players & Entities

• Regenerative Medical Technology Group Inc. (company) — Registrant
• MESO NUMISMATICS, INC. (company) — Former company name
• June 30, 2025 (date) — Quarterly period end date
• Boca Raton, Florida (location) — Principal executive offices location

FAQ

Filing Documents

• ea0253831-10q_regener.htm (10-Q) — 839KB
• ea025383101ex31-1_regener.htm (EX-31.1) — 10KB
• ea025383101ex31-2_regener.htm (EX-31.2) — 10KB
• ea025383101ex32-1_regener.htm (EX-32.1) — 4KB
• 0001213900-25-078525.txt ( ) — 5471KB
• mssv-20250630.xsd (EX-101.SCH) — 47KB
• mssv-20250630_cal.xml (EX-101.CAL) — 34KB
• mssv-20250630_def.xml (EX-101.DEF) — 258KB
• mssv-20250630_lab.xml (EX-101.LAB) — 429KB
• mssv-20250630_pre.xml (EX-101.PRE) — 274KB
• ea0253831-10q_regener_htm.xml (XML) — 563KB

FINANCIAL

PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025, and 2024 (unaudited) 2 Condensed Consolidated Statements of Stockholders' Deficit for the Three and Six Months Ended June 30, 2025, and 2024 (unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025, and 2024 (unaudited) 5 Notes to Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 40 Item 4.

Controls and Procedures

Controls and Procedures 40 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 42 Item 1A.

Risk Factors

Risk Factors 42 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 42 Item 3. Defaults Upon Senior Securities 42 Item 4. Mine Safety Disclosures 43 Item 5. Other Information 43 Item 6. Exhibits 43 i

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Regenerative Medical Technology Group Inc. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2025 2024 (Unaudited) * ASSETS Current assets Cash and cash equivalents $ 1,614,254 $ 1,165,820 Accounts receivable 36,676 22,605 Inventory 105,688 10,115 Prepaid expenses 154,864 49,685 Total current assets 1,911,482 1,248,225 Property and equipment, net 504,409 451,703 Other assets 7,264 7,264 Intangible assets, net 110,234 159,004 Right of use asset, net 273,461 275,256 Goodwill 1,679,978 1,679,978 Total assets $ 4,486,828 $ 3,821,429 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued liabilities $ 179,538 $ 563,703 Accrued interest 12,396,257 10,504,901 Customer advances 121,770 55,684 Derivative liability 6,166 4,689 Lease liability, current portion 64,176 63,540 Convertible notes payable, net 43,138 43,138 Notes payable-related parties 7,800 7,800 Notes payable, net 17,722,932 17,722,932 Total current liabilities 30,541,777 28,966,386 Long term liabilities Lease liability, net of current portion 209,285 211,716 Notes payable, net of current portion 2,757,016 1,999,999 Total liabilities 33,508,078 31,178,101 Commitments and contingencies (see Note 7) - - Stockholders' deficit Preferred stock, $ 0.001 par value: 1,050,000 shares authorized as Series AA: 1,050,000 issued and outstanding as of June 30, 2025, and December 31, 2024, respectively 1,050 1,050 Preferred stock, $ 0.001 par value; 1,000 shares authorized as Series CC: 1and 0 issued and outstanding as of June 30, 2025, and December 31, 2024, respectively 1 - Preferred stock, $ 0.001 par value; 10,000 shares authorized as Series DD: 9,870 issued and outstanding as of June 30, 2025, and December 31, 2024, respectively 10 10 Common stock, $ 0.001 par value: 100,000,000 shares authorized: 12,538,968 issued and out

View Full Filing

View this 10-Q filing on SEC EDGAR